| scholarly article | Q13442814 |
| P50 | author | Helena Persson | Q55298352 |
| Thomas Litman | Q56568931 | ||
| Beatriz Morancho | Q57324555 | ||
| Joaquin Arribas | Q80171901 | ||
| Stine Pedersen | Q38323001 | ||
| P2093 | author name string | Rolf Søkilde | |
| Carlos Rovira | |||
| Andrej Gorbatenko | |||
| Ester E Sorensen | |||
| Inga Newie | |||
| P2860 | cites work | Constitutively active ErbB2 regulates cisplatin-induced cell death in breast cancer cells via pro- and antiapoptotic mechanisms. | Q50639844 |
| Oncogenic p95HER2 regulates Na+-HCO3- cotransporter NBCn1 mRNA stability in breast cancer cells via 3'UTR-dependent processes. | Q51526662 | ||
| MicroRNA-503 promotes tumor progression and acts as a novel biomarker for prognosis in oesophageal cancer. | Q54171415 | ||
| Truncated ErbB2 receptor enhances ErbB1 signaling and induces reversible, ERK-independent loss of epithelial morphology | Q56825025 | ||
| MYB oncogene amplification in hereditary BRCA1 breast cancer | Q73083781 | ||
| MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer | Q21195215 | ||
| Comprehensive molecular portraits of human breast tumours | Q24630844 | ||
| MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer | Q24645663 | ||
| miR-221 overexpression contributes to liver tumorigenesis | Q24646374 | ||
| MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1 | Q24648241 | ||
| The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity | Q27010233 | ||
| MicroRNA biogenesis pathways in cancer | Q27013841 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| MicroRNA signatures in human cancers | Q27860962 | ||
| MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer | Q28114800 | ||
| The myb gene family in cell growth, differentiation and apoptosis | Q28137891 | ||
| The conserved DNA binding domain mediates similar regulatory interactions for A-Myb, B-Myb, and c-Myb transcription factors | Q28205623 | ||
| Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells | Q28213093 | ||
| Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. | Q28215016 | ||
| Treatment of HCV infection by targeting microRNA | Q29547712 | ||
| Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. | Q33180996 | ||
| ISMARA: automated modeling of genomic signals as a democracy of regulatory motifs | Q33564556 | ||
| microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers | Q33576814 | ||
| The miR-424(322)/503 cluster orchestrates remodeling of the epithelium in the involuting mammary gland. | Q33588077 | ||
| Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1 | Q34342166 | ||
| B-Myb, cancer, senescence, and microRNAs | Q35164933 | ||
| Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease | Q35584190 | ||
| Cell cycle regulation by the B-Myb transcription factor. | Q35587968 | ||
| Netrin-4 as a biomarker promotes cell proliferation and invasion in gastric cancer. | Q35833147 | ||
| Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells | Q35963023 | ||
| Myb proteins: angels and demons in normal and transformed cells | Q36603616 | ||
| HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer | Q36903047 | ||
| MYB function in normal and cancer cells | Q37198576 | ||
| A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis | Q37233360 | ||
| MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion. | Q37323030 | ||
| p95HER2 and breast cancer | Q37846003 | ||
| Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma. | Q38275143 | ||
| In vitro and in vivo analysis of B-Myb in basal-like breast cancer | Q38358546 | ||
| Distinct changes in gene expression induced by A-Myb, B-Myb and c-Myb proteins | Q38358724 | ||
| miRNA-503 Promotes Tumor Progression and Is Associated with Early Recurrence and Poor Prognosis in Human Colorectal Cancer | Q38784427 | ||
| MicroRNA-503 represses epithelial-mesenchymal transition and inhibits metastasis of osteosarcoma by targeting c-myb | Q38803579 | ||
| MiR-221/222 promote human glioma cell invasion and angiogenesis by targeting TIMP2. | Q38904607 | ||
| ErbB2 upregulates the Na+,HCO3(-)-cotransporter NBCn1/SLC4A7 in human breast cancer cells via Akt, ERK, Src, and Kruppel-like factor 4. | Q39088649 | ||
| Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence. | Q39216531 | ||
| A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers | Q39639513 | ||
| Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. | Q40144433 | ||
| Myb protein specificity: evidence of a context-specific transcription factor code. | Q40634908 | ||
| Expression of A-myb, but not c-myb and B-myb, is restricted to Burkitt's lymphoma, sIg+ B-acute lymphoblastic leukemia, and a subset of chronic lymphocytic leukemias. | Q41223715 | ||
| NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer | Q41925146 | ||
| A novel MAPK-microRNA signature is predictive of hormone-therapy resistance and poor outcome in ER-positive breast cancer. | Q42468088 | ||
| Linking Myb to the cell cycle: cyclin-dependent phosphorylation and regulation of A-Myb activity | Q42796307 | ||
| B-myb rescues ras-induced premature senescence, which requires its transactivation domain | Q42826690 | ||
| Strong association between c-myb and oestrogen-receptor expression in human breast cancer. | Q43954768 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | limma | Q112236343 |
| edgeR | Q113334690 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3352 | |
| P577 | publication date | 2019-03-04 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503 | |
| P478 | volume | 9 |
| Q92591538 | Role of miR-221/222 in Tumor Development and the Underlying Mechanism | cites work | P2860 |
Search more.